UK Markets closed

Biocartis Group NV (BCART.BR)

Brussels - Brussels Delayed price. Currency in EUR
Add to watchlist
3.01000.0000 (0.00%)
At close: 05:35PM CET
Full screen
Loading interactive chart…
  • Globe Newswire

    Press release Biocartis Group NV: Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes

    PRESS RELEASE: 25 January 2022, 07:00 CET Large UK Study Shows Rapid EGFR Testing with Idylla™ Alongside NGS Has Potential to Enhance Lung Cancer Patient Health Outcomes Lung cancer accounts for the largest number of cancer deaths worldwide102 Idylla™ EGFR Mutation Test (CE-IVD) results of lung adenocarcinoma patients1 were compared with NGS 6 percent of the patients died before the NGS report was available; of the 17 patients whose condition deteriorated rapidly, 3 (18 percent) were identified

  • Globe Newswire

    Press release Biocartis Group NV: BIOCARTIS MEETS 2021 KEY OBJECTIVES

    PRESS RELEASE: REGULATED INFORMATION10 January 2022, 07:00 CET BIOCARTIS MEETS 2021 KEY OBJECTIVES Mechelen, Belgium, 10 January 2022 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announced the Company has achieved its 2021 key business objectives which were focused on three performance indicators: expanded installed base of its rapid and easy-to-use Idylla™ molecular diagnostics platform, increased Idylla™ commercial

  • Globe Newswire

    Press release Biocartis Group NV: Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant

    PRESS RELEASE: 9 December 2021, 07:00 CET Biocartis’ Idylla™ SARS-CoV-2 testing Successfully Detects Omicron Variant Mechelen, Belgium, 9 December 2021 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that the Company performed an in-silico analysis which concluded that the Idylla™ SARS-CoV-2 Test (CE-IVD) and the Idylla™ SARS-CoV-2/Flu/RSV1 Panel (CE-IVD) detect the currently available B.1.1.529/Omicron